In p53 and RB deficient SCLC murine models, a selective CDK7 inhibitor, YKL-5-12, was tested in association with anti-topoisomerase I, topotecan, and immune checkpoint inhibitors (ICIs). The gene discussed is TP53; the disease is small cell lung carcinoma.